Phase 1 psychedelic research trials
Data as of 11 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
Phase 1 is a registry phase value. First studies in people, usually small, looking at how a substance is tolerated and processed by the body. A phase describes how a study is designed, not what it found.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 254 registered studies are counted on this page.
Which substances
Counts per substance hub. Ketamine is limited to studies classified as psychiatric research, and records about disease-modifying therapy that match the abbreviation DMT are removed.
| Substance hub | Studies |
|---|---|
| Psilocybin | 111 |
| MDMA | 35 |
| LSD | 20 |
| DMT | 26 |
| 5-MeO-DMT | 12 |
| Ayahuasca | 3 |
| Ketamine | 76 |
| Mescaline | 2 |
| Ibogaine | 3 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 54 | 21% |
| Not yet recruiting | 17 | 7% |
| Enrolling by invitation | 1 | 0% |
| Active, not recruiting | 16 | 6% |
| Completed | 129 | 51% |
| Terminated | 16 | 6% |
| Withdrawn | 8 | 3% |
| Status not reported | 13 | 5% |
Countries
Country is taken from the study's linked research site. 4 of 254 records have no country on file. The top 10 countries are shown.
| Country | Studies | Share |
|---|---|---|
| United States | 154 | 61% |
| Switzerland | 32 | 13% |
| United Kingdom | 15 | 6% |
| Canada | 11 | 4% |
| Netherlands | 7 | 3% |
| Australia | 5 | 2% |
| Brazil | 5 | 2% |
| Austria | 3 | 1% |
| Spain | 3 | 1% |
| Finland | 3 | 1% |
When studies started
| Start year | Studies |
|---|---|
| 2024 to 2026 | 94 |
| 2020 to 2023 | 83 |
| 2015 to 2019 | 44 |
| 2010 to 2014 | 20 |
| Before 2010 | 13 |
Study design
- 254 interventional and 0 observational studies.
- Median planned or actual enrolment is 24 participants (range 1 to 200, across 247 records that report it).
Topics named in study titles
A keyword match on registered titles, so one study can appear under more than one topic and a study can be missed. It describes what titles mention, nothing more.
| Topic | Studies |
|---|---|
| Depression and mood | 52 |
| Healthy volunteers | 48 |
| Other substance use | 20 |
| Trauma and PTSD | 16 |
| Pain and headache | 15 |
| Cancer and end of life | 8 |
| Obsessive-compulsive disorder | 8 |
| Alcohol use | 6 |
Most recently started studies
The 25 studies with the latest start dates, newest first. The order is not a ranking. Each ID links to its own ClinicalTrials.gov record.
| Registry ID | Title as registered | Status | Phase | Country | Start |
|---|---|---|---|---|---|
| NCT07719088 | Psilocybin Effects on Healthy Aging Biomarkers and Purpose in Life | Not yet recruiting | Phase 1 | United States | 2026-12 |
| NCT07818720 | MLS101 Study in PMDD | Not yet recruiting | Phase 1 | Not reported | 2026-12 |
| NCT07833761 | ADEPT Psilocybin-Assisted Therapy With DBT for Borderline Personality Disorder | Not yet recruiting | Phase 1 | United States | 2026-12 |
| NCT07818564 | Pilot Study on the Effects of Psilocybin on Belief Updating and Insight Formation | Recruiting | Phase 1 | United States | 2026-11 |
| NCT07683988 | Oral and Sublingual Ketamine | Not yet recruiting | Phase 1 | Canada | 2026-10 |
| NCT07433452 | The Effects of Psilocybin in Healthy Volunteers: Psychological, Biochemical and Electrophysiological Biomarkers. | Not yet recruiting | Phase 1 | Not reported | 2026-09 |
| NCT07693257 | Neural Effects of Intravenous N,N-dimethyltryptamine (DMT) | Not yet recruiting | Phase 1 | United States | 2026-09 |
| NCT07693153 | The Effects of Psilocybin on Social Connectedness | Not yet recruiting | Phase 1 | United States | 2026-08 |
| NCT07499583 | Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder | Not yet recruiting | Phase 1 | United States | 2026-08 |
| NCT07406828 | Psilocybin After Trauma Surgery for Pain | Not yet recruiting | Phase 1 | United States | 2026-07 |
| NCT07503002 | Shortened LSD Intervention for Major Depressive Disorder | Not yet recruiting | Phase 1 | United States | 2026-07 |
| NCT07607938 | Psilocybin as a Novel Therapy for Residual Anhedonia | Recruiting | Phase 1 | United States | 2026-07 |
| NCT07610135 | Psilocybin Efficacy With or Without Pimavanserin Pretreatment | Recruiting | Phase 1 | United States | 2026-07 |
| NCT07747324 | Effects of a Sigle Dose of Ayahuasca in Patients With Psychogenic Non-epileptic Seizures: an Open Label Clinical Trial | Recruiting | Phase 1 | Brazil | 2026-07 |
| NCT07506395 | Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder | Recruiting | Phase 1 | United States | 2026-05 |
| NCT07542145 | MDMA Assisted Therapy for BN | Recruiting | Phase 1 | United States | 2026-05 |
| NCT07584720 | Study of Midomafetamine in Healthy Adults | Active, not recruiting | Phase 1 | United States | 2026-04 |
| NCT07516405 | Safety and Tolerability Trial of Psilocybin in Healthy Older Adults | Recruiting | Phase 1 | United States | 2026-04 |
| NCT07540494 | Pharmacokinetics and Safety of GH001 Delivered Via a GH001 Aerosol Delivery System in Healthy Subjects | Completed | Phase 1 | United States | 2026-04 |
| NCT07444788 | Acute Effects of Intravenous 5-MeO-DMT in Healthy Participants | Recruiting | Phase 1 | Switzerland | 2026-03 |
| NCT03606538 | MDMA in Subjects With Moderate Hepatic Impairment and Subjects With Normal Hepatic Function | Not yet recruiting | Phase 1 | United States | 2026-03 |
| NCT07494214 | Acute Analgesic Effects of MDMA on Experimentally Induced Acute Pain, Hyperalgesia and Allodynia in Healthy Participants | Recruiting | Phase 1 | Switzerland | 2026-03 |
| NCT07462559 | KF2025#1 Trial: Ketamine, Cannabidiol and Cobicistat Interaction Study | Not yet recruiting | Phase 1 | Finland | 2026-03 |
| NCT07386730 | A Study of Psychedelics in Healthy Older Adults With Low Well-being | Recruiting | Phase 1 | United States | 2026-03 |
| NCT07053917 | Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability | Recruiting | Phase 1 | United States | 2026-02 |
Other substance hubs
Psilocybin | MDMA | LSD | DMT | 5-MeO-DMT | Ayahuasca | Ketamine | Ibogaine
Registry status hubs
Recruiting | Not yet recruiting | Active, not recruiting | Enrolling by invitation | Completed | Terminated | Suspended | Withdrawn
Phase hubs
Early Phase 1 | Phase 2 | Phase 3 | Phase 4 | Phase not applicable